Citizens JMP raised the firm’s price target on Nuvation Bio (NUVB) to $10 from $8 and keeps an Outperform rating on the shares. Safusidenib, in a Phase 2 Japanese glioma study, significantly outperformed based on overall response rate, compared to the Phase 3 INDIGO study of vorasidenib, the analyst tells investors in a research note. Nuvation Bio plans to move forward with safusidenib in a higher-grade glioma setting, which is a sensible path, Citizens says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Nuvation Bio price target raised to $11 from $7 at Wedbush
- Midday Fly By: Target reports mixed Q3, Adobe buying Semrush
- Nuvation Bio initiated with a Buy at B. Riley
- Positive Outlook on Nuvation Bio’s Safusidenib Driven by Promising Clinical Data and Strategic Focus
- Nuvation Bio Reports Positive Phase 2 Study Results